BridgeBio Pharma Inc
NASDAQ:BBIO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.35
43.89
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
BridgeBio Pharma Inc
BridgeBio Pharma Inc
Interest Income Expense
BridgeBio Pharma Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BridgeBio Pharma Inc
NASDAQ:BBIO
|
Interest Income Expense
-$56.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$948m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.4B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-15%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$598m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$990m
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BridgeBio Pharma Inc
Glance View
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 576 full-time employees. The company went IPO on 2019-06-27. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561, BBP-711, BBP-631 and BBP-454.
See Also
What is BridgeBio Pharma Inc's Interest Income Expense?
Interest Income Expense
-56.7m
USD
Based on the financial report for Sep 30, 2024, BridgeBio Pharma Inc's Interest Income Expense amounts to -56.7m USD.
What is BridgeBio Pharma Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-30%
Over the last year, the Interest Income Expense growth was 16%. The average annual Interest Income Expense growth rates for BridgeBio Pharma Inc have been -11% over the past three years , -30% over the past five years .
You don't have any saved screeners yet
